Experience

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760,000 shares of common stock of Intercept Pharmaceuticals, Inc. …

Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…

Davis Polk advised Zai Lab Limited in connection with its follow-on offering of $230 million of American Depositary Shares representing 9,019,608 ordinary shares of the company. The ADSs…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8 million follow-on offering of common stock of Magenta Therapeutics,…

Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…

Davis Polk advised the several underwriters in connection with the follow-on offering of 5,263,158 shares of common stock of Natera, Inc. for total gross proceeds of approximately $100…

Davis Polk advised the representatives of the several underwriters in connection with a $191.5 million initial public offering of common stock of Turning Point Therapeutics, Inc…

Davis Polk advised a sales agent in connection with the establishments of an SEC-registered at-the-market offering program by Millendo Therapeutics, Inc. of up to $50 million gross…

Davis Polk advised the joint book-running managers and the lead manager in connection with a $119 million public offering of common stock by NanoString Technologies, Inc. The common…

Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock for an aggregate price to the public of approximately $111.4…